Nanoparticle-based combination therapy toward overcoming drug resistance in cancer

Che Ming Jack Hu, Liangfang Zhang

研究成果: Review article同行評審

438 引文 斯高帕斯(Scopus)


The use of multiple therapeutic agents in combination has become the primary strategy to treat drug resistant cancers. However, administration of combinatorial regimens is limited by the varying pharmacokinetics of different drugs, which results in inconsistent drug uptake and suboptimal drug combination at the tumor sites. Conventional combination strategies in aim to maximize therapeutic efficacy based on maximum tolerated dose does not account for the therapeutic synergism that is sensitive to both dosing and scheduling of multiple drugs. In the present review, we will discuss the development of multidrug-loaded nanoparticles against drug resistant cancers. Nanoparticle-based combination therapy against experimental multidrug resistant (MDR) cancer models will be summarized. In addition, we will highlight the recent advances in nanoparticle-based combination strategies against clinical cancer drug resistance, including co-encapsulation of drugs with different physicochemical properties, ratiometric control over drug loading, and temporal sequencing on drug release. These emerging strategies promise novel and better tailored combinatorial regimens for clinical cancer treatment.

頁(從 - 到)1104-1111
期刊Biochemical Pharmacology
出版狀態Published - 2012 四月 15

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Pharmacology

指紋 深入研究「Nanoparticle-based combination therapy toward overcoming drug resistance in cancer」主題。共同形成了獨特的指紋。